The proportion of tumor- infiltrated dendritic cells (DCs) and effector CD8+ T cells increased, while the proportion of immunosuppression- related Tregs decreased in the sulfatinib treatment group, and the proportion changes became more obvious as the dose increased. This evidence concerns the gene CD8A and neoplasm.